Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Accumulated Expenses: 2009-2012

Historic Other Accumulated Expenses for Ani Pharmaceuticals (ANIP) over the last 4 years, with Dec 2012 value amounting to $502,452.

  • Ani Pharmaceuticals' Other Accumulated Expenses fell 94.46% to $112,784 in Q1 2013 from the same period last year, while for Mar 2013 it was $112,784, marking a year-over-year decrease of 94.46%. This contributed to the annual value of $502,452 for FY2012, which is 79.74% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Other Accumulated Expenses of $502,452 as of FY2012, which was down 79.74% from $2.5 million recorded in FY2011.
  • In the past 5 years, Ani Pharmaceuticals' Other Accumulated Expenses ranged from a high of $2.5 million in FY2011 and a low of $502,452 during FY2012.
  • For the 3-year period, Ani Pharmaceuticals' Other Accumulated Expenses averaged around $1.6 million, with its median value being $1.7 million (2010).
  • As far as peak fluctuations go, Ani Pharmaceuticals' Other Accumulated Expenses skyrocketed by 78.38% in 2010, and later tumbled by 79.74% in 2012.
  • Yearly analysis of 4 years shows Ani Pharmaceuticals' Other Accumulated Expenses stood at $942,922 in 2009, then spiked by 78.38% to $1.7 million in 2010, then surged by 47.43% to $2.5 million in 2011, then crashed by 79.74% to $502,452 in 2012.